Skip to main content

Table 1 MIC50, MIC90, and percent susceptible, intermediate or resistant for 105 CF P. aeruginosa by reference broth microdilution and ETEST

From: Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

Antibiotic

BMD

ETEST

MIC50 (µg/ml)

MIC90 (µg/ml)

S/I/R (%)

MIC50 (µg/ml)

MIC90 (µg/ml)

S/I/R (%)

ATM

8

64

58/10/32

8

≥ 256

54/11/35

FEP

8

≥ 128

50/20/30

16

≥ 256

32/21/47

CAZ

4

64

68/10/22

4

≥ 256

74/6/20

CZA

2/4

8/4

90/-/10

2/4

16/4

88/-/12

C/T

1/4

4/4

92/2/6

2/4

8/4

87/6/7

CIP

2

8

27/14/59

2

≥ 32

27/14/59

LVX

4

16

24/13/63

16

≥ 32

20/8/72

MEM

1

32

58/6/36

1

≥ 32

55/5/40

TZP

8/4

256/4

67/13/20

8/4

≥ 256/4

58/15/27

TOB

2

32

63/13/24

4

64

50/20/30

  1. ATM: aztreonam; FEP: cefepime; CAZ: ceftazidime; CZA: ceftazidime–avibactam; C/T: ceftolozane–tazobactam; CIP: ciprofloxacin; LVX: levofloxacin; MEM: meropenem; TZP: piperacillin–tazobactam; TOB: tobramycin; S: susceptible; I: intermediate; R: resistant; MIC50: minimum inhibitory concentration of 50% of isolates; MIC90: minimum inhibitory concentration of 90% of isolates